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METHODS: This retrospective cohort analysis utilized claims from a large national
health plan. Includedweremembers aged 65-89 years, with continuous enrollment
between Jan-2008 and Dec-2009. Patients with T2DM (cases) were propensity
matched 1:1 with non-diabetes patients (controls) by age, gender, ethnicity, geo-
graphic location, low-income status, and plan type. To assess burden of illness,
all-cause health care costs for 2009 were calculated as the sum of all medical and
pharmacy claims (based on ICD-9-CM and GPI codes), and were compared descrip-
tively for cases and controls. In addition, costs directly attributable to diabeteswere
evaluated for the case cohort (based on ICD-9-CM 250.xx and prescriptions for
anti-hyperglycemic agents). RESULTS: The analysis included 179,203 cases and
matched controls. There were no significant differences at baseline between co-
horts with respect to matched variables, however, cases had a significantly higher
mean (SD) Deyo-Charlson Comorbidity Index compared to controls (2.47 versus
0.77 respectively; p0.0001). Mean (SD) all-cause healthcare costs per patient per
year were significantly higher for cases versus controls for in-patient hospitaliza-
tion ($1,120$4,425 vs. $712$3,230), outpatient visits ($5,475$15,640 vs.
$3,620$11,149), office visits ($1,666$3,652 vs. $1,358$3,492), ER visits
($288$868 vs. $219$759), pharmacy costs ($2,195$2,807 vs. $1,342$2,438) and
total healthcare costs ($10,40619,959 vs. $6,993$14,836) respectively, all
p0.0001. The mean diabetes attributable total healthcare cost for the case cohort
was $3,588$9,270 per patient per year. CONCLUSIONS: All cause healthcare costs
were significantly higher for patients with T2DM than for matched controls, high-
lighting the serious burden of illness in this Medicare Advantage population.
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ECONOMIC BURDEN OF CUSHING’S DISEASE: A POPULATION ANALYSIS OF
DIRECT MEDICAL COSTS AND UTILIZATION
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OBJECTIVES: Cushing’s disease (CD), a rare pituitary disorder, is associated with
significant morbidity and mortality, but the economic impact is unknown. This
study assessed the annual healthcare costs and utilization of CD patients.
METHODS: Administrative claims from 2004-2008 of a large population with com-
mercial or Medicare-supplemental insurance in the USwere analyzed. CD patients
were those with medical claims for Cushing’s syndrome (ICD-9-CM: 255.0) and
either benign pituitary adenoma (227.3) or hypophysectomy (07.6). Each CD patient
was age- and gender-matched to four patients with non-functioning pituitary ad-
enoma (NFPA) and ten population controls (PC). NFPA was identified as benign
pituitary adenoma without Cushing’s syndrome, acromegaly (253.0) or hyperpro-
lactinemia (253.1). Comorbid conditions and annual direct healthcare costs were
compared between cohorts by calendar year. RESULTS:The study identified 877 CD
patients (79% female; average age 43 years). Hypertension (43% [CD] vs. 24% [NFPA]
vs. 17% [PC]), diabetes (29% vs. 13% vs. 7%) and hyperlipidemia (27% vs. 21% vs. 14%)
were the most common comorbidities in CD patients and more prevalent than in
NFPApatients and PC (all p0.05). CD patients had significantly higher total health-
care costs than NFPA patients and PC in 2004-2008; the difference between cohorts
increased over time. In 2008, average healthcare costs were $26,440 among CD
patients, compared to $13,708 in NFPA patients and $5,954 in PC (both p0.05).
Approximately one-third of total costs among CD patients were attributable to
CD-related services. CD patients were more likely to have inpatient admissions
(20.7% vs. 15.8% [NFPA] vs. 7.1% [PC], both p0.01), had more frequent outpatient
hospital visits (6.5 vs. 3.8 vs. 1.8, both p0.01), and receivedmoremedications than
NFPA patients and PC (means: 10.0 vs. 7.4 vs. 4.7, both p0.01). CONCLUSIONS: CD
patients had more comorbidities than NFPA patients and PC, and incurred signif-
icantly higher annual healthcare costs.
PDB66
COSTS OF THE PHARMACEUTICAL PROGRAM TO TREAT T2DM PATIENTS FROM
HIPERDIA: GOVERNMENT HEALTH CARE PROGRAM FOR DIABETES AND
HYPERTENSION POPULATION UNDER THE BRAZILIAN PUBLIC HEALTH CARE
SYSTEM
Nasciben V, Melo TG
Boehringer Ingelheim Brazil, Sao Paulo, Brazil
OBJECTIVES: Diabetes is a chronic disease that requires continuing care to reduce
the risk of long-term complications. In this sense it is important tomaintain a good
therapeutic arsenal providing good treatment to mantain type 2 diabetes (T2DM)
and hypertension under control, preventing complications. We decided to assess
the costs of the HIPERDIA program with medication provided by the government
for a future cost-effectiveness research. METHODS: HIPERDIA is a program for
monitoring hypertensive and diabetic patients under care in the public healthcare
system. Based on that database, we searched the number of patients under treat-
ment from 2005 to 2010 and also the number of doses of the drugs (glibenclamide
and metformin) available to control T2DM (Datasus/Hiperdia). Also, we looked at
the Brazilian price database (Banco de Preços) the minimum and the maximum
price paid by the government for those drugs to calculate their total costs in the
program. RESULTS: From 2002 to 2010, we found a total of 1,067,754 patients using
glibenclamide 5 mg and 662,519 patients under metformin 850 mg, however it was
not clear the number of patients taking both. The average dailydosewas 1.79 tablet
for glibenclamide and 1.74 for metformin. In the price database from the govern-
ment, we found that the average price paid for glibenclamide was R$ 0.008/daily
unit (ranging from R$ 0.007 to 0.04) and for metformin R$ 0.026/daily unit (ranging
from R$ 0.023 to 0.098). From January 2009 to August 2010 the total cost of this
programwith these 2 drugs reached R$ 1,567,145 and our projections showed that,
since 2002, the government spent about R$ 9 million. CONCLUSIONS: Generics
generated a huge price pressure for those drugs in Brazil and with this scenario it
seems to be difficult to predict the plans to update the drug list to provide more
effective treatments for this population.
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OBJECTIVES: This project presents an analysis of IT processes on variations of
prescribing patterns for patients diagnosedwith diabetes type II, following the first
study on electronic billing and its association with diabetic drug prescribing
(Huttin/Wong,2010).METHODS:A sample of 610 patients is extracted from the CDC
physician survey.IT processes include electronic medical records (EMR), with or
without patient demographics, computerized orders for Rx, tests, lab results, notes
from nurses and physicians, public health reporting. Several hierarchical cluster-
ing methods are tested to identify various stages of IT processes and the impact of
IT is analyzed with non parametric tests (analysis of variance) on prescribing
patterns. RESULTS: Two HB clustering methods (average method and ward) iden-
tify three clusters representing different stages of IT processes: physicians using no
IT at all (80.76%) and two levels of IT operations in practices (cluster 2: 17.33 %;
cluster 3: 1.91%). The dendogram with the AL method presents clearer separation
than the dendogram with the ward method. Variations in drug prescribing is sig-
nificant between clusters, using the scoring savage test:21 for cluster 1, 16.85 for
cluster 2, 4.4 for cluster 3 (P value 0.01). The analysis on new drugs does not show
different prescribing patterns; however, the number of injectables (insulin) per
patient is significantly higher in cluster 2 than 1 (0.51 verus 0.39). Different patterns
of IT processes are also identified within cluster 2 and other clustering methods
among grouping and similarity computations (e.g. Shusaku et als,2004)are tested to
analyze the propagation of IT processes among the practices of this dataset (gen-
eralisation tested with a similarity matrix). CONCLUSIONS: This project can be
used for analysis and management of IT processes inside clinical systems and
control for their effects on physician prescribing behaviours.Results confirm that in
addition to ebilling, different patterns of IT processes have an impact on treatment
regimens (especially affecting insulin or insulin/OAD combinations). This can com-
plement Koro et als study (2004).
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ASSESSING LIFEYEARS SAVED FROM 2000 TO 2010 IN CHINA DUE TO NOVO
NORDISK INSULIN
Henriksen O, Jain P, Nielsen OK
Novo Nordisk, Inc., Bagsvaerd, Denmark
OBJECTIVES: Insulin and other diabetes treatments are generally considered cost
effective treatment options as they reduce the incidence of complications, increase
life expectancy and improve quality of life. This paper quantifies in a new model
the life years saved in the Chinese diabetic population between 2000 and 2010 due
to sales of Novo Nordisk insulin.METHODS: The CORE diabetes model was used to
make projections of long-term survival rates for peoplewith type 2 diabetes treated
with defined therapies; modern insulin monotherapy (MI Mono), Modern Insulin
combined with Oral Anti Diabetics (OAD), human insulin combined with OAD (HI
OAD) and human insulin monotherapy (HI Mono). In the human insulin scenarios,
the base case cohort characteristics were based on the Chinese DiabCare data for
1998 (mean age 56.71 years, 58% male, duration of diabetes 7 years, HbA1c 8.81%).
The modern insulin scenarios (introduced around 2005) are based on cohort char-
acteristics observed in the Chinese PRESENT study (mean age 57.21 years, 51%
male, duration of diabetes 6 years, HbA1c 7.93%). Treatment effects in the four
interventions modelled; MI Mono, MI OAD, HI OAD and HI Mono relied on pub-
lished sources (HbA1c;1%,1.82%,1.2% and 0.7% respectively). The annual size
of the population treated was calculated using annual Novo Nordisk sales and
average daily insulin dosage as observed in the DiabCare China study. This process
was then repeated for each year from 2000 to 2010 making it possible to cumulate
the number of life years saved. RESULTS: The undiscounted life expectancy for the
4 different baseline cohortsmodelled in the CORE diabetesmodel was improved by
2.9, 2.7, 2.2, 1.7 forMIOAD,MIMono, HI OAD,HIMono respectively.CONCLUSIONS:
The cumulated undiscounted life years saved between 2000 and 2010 was esti-
mated at 136.198.66 due to treatment with Novo Nordisk insulin in China.
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TYPE-2 DIABETES PATIENTS IN GERMANY
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OBJECTIVES: Exenatide and liraglutide are the two therapeutic options in the GLP-1
anti-diabetic medication class, to improve glycemic control in adults with type 2
diabetes (T2D). This study evaluated patient and prescriber characteristics, treat-
ment patterns, average daily dose (ADD), and glycemic control of patients initiating
GLP-1 medications in Germany. METHODS: The LifeLink™ EMR-EU database con-
tains records for over 15 million German patients and 3,000 physicians. The cohort
included patients who initiated exenatide or liraglutide during the index period
(01/01/2009 - 04/30/2010). Patients also had 180 days history, pre-index; 90-540
days follow-up, post-index; and a T2D diagnosis (ICD-10 E10-E14), pre-index. Uni-
variate tests were conducted at .05. RESULTS: The cohort included 692 patients
(exenatide 292, liraglutide 400): mean (SD) age 59 (10) years, 59%male. Diabetolo-
gists prescribed liraglutidemore frequently than exenatide (65% vs. 35%) compared
to non-diabetologists (51% vs. 49 %). Choice of GLP-1 was not associated with pa-
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tient age, sex, number of pre-index antidiabetic medications (1.90.9), pre-index
HbA1c (8.21.5%), or Charlson Comorbidity Index (0.450.78, all p.05). Mean (SD)
ADDwas 16.7mcg (9.22; label range 10-20mcg) for exenatide patients and 1.43mg
(0.69, label range 0.6-1.8 mg) for liraglutide patients. Among patients with post-
index HbA1c tests, mean values did not differ at the first (7.9), second (7.8), or third
(7.8, all p.05) tests. Exenatide patients were more likely than liraglutide patients
to continue pre-index anti-diabeticmedications (67.1% vs. 60.3%, p.027) or to start
concomitant anti-diabeticmedications at index (32.2% vs. 25.0%, p.013); however,
exenatide patients were less likely to augment treatment post-index (15.8% vs.
22.5%, p.027). Post-index, 9.3% exenatide and 10% liraglutide patients discontin-
ued GLP-1 therapy (p.05). CONCLUSIONS: Results suggest that some differences
exist between German patients initiating exenatide or liraglutide, with respect to
prescribing physician specialty, pre-and post-index treatment patterns, and ADD.
Both GLP-1s show comparable post-index HbA1c.
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OBJECTIVES: This study describes baseline characteristics and prior antidiabetic
therapy of patients in an electronic medical record (EMR) prescribed liraglutide, a
once-daily GLP-1 agonist, relative to non-liraglutide patients. METHODS: Adults
(18 years) with T2DM, a new prescription for liraglutide from 3/10/2010 to 7/16/
2010 (index date), and EMR activity395 days pre-index to1 day post-index were
identified. Demographics, comorbidities, and pre-index antidiabetic prescriptions
orders were compared to adults with T2DM, 1 non-liraglutide antidiabetic order
from1/1/2010 to 7/16/2010 (index date), and EMR activity395 days pre-index to1
day post-index. Bootstrapping was used to provide robust mean (95% CI) estimates
for comparison patients due to sample size (n247,922). RESULTS:Of 1,162 liraglu-
tide patients, 58.8% were female and mean (95% CI) age was 55.5 (54.9, 56.2) years
vs. 53.0% female and 60.9 (60.1, 61.6) years for comparison patients. For liraglutide
vs. comparison patients, mean baseline HbA1c was 8.1% (8.0, 8.2) vs. 7.6% (7.5, 7.8),
BMI was 38.3 kg/m2 (37.8, 38.8) vs. 34.1 kg/m2 (33.6, 34.6), body weight was 109.5 kg
(108.0, 111.0) vs. 96.7 kg (95.1, 98.3). Comorbidities in liraglutide vs. comparison
patients included dyslipidemia (87.1% vs. 79.2%), hypertension (73.6% vs. 73.8%),
and cardiovascular disease (18.2% vs. 22.4%). Of liraglutide patients, 5.6% were
antidiabetic drug naive pre-index vs. 42.0% of comparison patients. Themost com-
mon antidiabetics prescribed any time the year pre-index were metformin and
sulfonylureas, respectively, for liraglutide (64.5%, 37.5%) and comparison (28.7%,
19.6%) patients, followed by insulin (33.8% liraglutide vs. 19.6% comparison). Pre-
index orders formultiple antidiabetics occurred in 75.6% of liraglutide and 22.5% of
comparison patients (p0.01 for all comparisons except hypertension p.05).
CONCLUSIONS: Early data suggest that liraglutide is being utilized in very obese
patients who failed to achieve HbA1c goal on other antidiabetics. Longitudinal
research is warranted to assess liraglutide outcomes and changes in antidiabetics
post-liraglutide.
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CHARACTERISTICS OF EARLY ADOPTERS OF EXPENSIVE MEDICATIONS
Juarez DT, Davis J, Fujimoto R, Chung RS
Hawaii Medical Service Association, Honolulu, HI, USA
OBJECTIVES: To examine characteristics of physicians who are early adopters of
new expensive drugsMETHODS: Retrospective analysis of pharmacy claims from
2006-2010 for 3 expensive diabetes drugs (exenatide, saxagliptin, and sitagliptin)
identified by medical directors and pharmacists at large health plan in Hawaii. We
examined how physician specialty and urban setting affected likelihood of being
an early prescriber. We calculated total paid costs and days supply by quarter for
each physician. We also examined whether same physicians tended to be early
adopters of all drugs. RESULTS: Characteristics of early adopters differed by med-
ication. For saxagliptin, during first 2 quarters, 53% of prescriptions were made by
internists, 30%by general/family practitioners, 17%by other specialists and1%by
endocrinologists. This distribution stayed fairly stable over time. In contrast, for
exenatide, in first 2 quarters usage was highest for endocrinologists (28%), Medic-
aid providers (29%) or other specialists (25%). By the end of 2010, however, most
exenatide prescriptions were being made by internists or general/family practitio-
ners. The trends for sitagliptin were similar to that of exenatide with endocrinol-
ogists (32%), Medicaid (34%) and other specialists (30%) being early adopters with a
shift towardmore prescriptions by primary care physicians. Early adopters tended
to be in urban areas. 75% of physicians were early prescribers of one drugs, 25%
were early prescribers of two drugs, and none were early prescribers of all three
medications. CONCLUSIONS: Research of this nature may enable us to target in-
tervention programs to promote cost-effective prescribing patterns.
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TWO-WAY INTERACTION EFFECT ANALYSIS OF DIABETES COMPLICATIONS
ON HEALTH COSTS AND HEALTH OUTCOMES IN MEDICARE INPATIENTS
Wang X
University of Louisville, Louisville, KY, USA
OBJECTIVES: The purpose of this project is to investigate the interaction effects of
diabetes complications on Medicare expenditures, length of hospitalization, claim
frequency and mortality of diabetes inpatients in the Medicare population.
METHODS: The analysis is based on inpatient claims data with 244,299 records for
the year 2004, from CMS (the Centers for Medicare and Medicare Services) chronic
condition data warehouse. In this study, the RXMATCH function, summary statis-
tics and 0-1 indicator functions are used to generate the predictor variables, heart
disease, kidney disease, neurologic disorder, ocular disease and hypertension. The
generalized linearmodel with a gammadistribution is employed for the analysis of
interaction effects of complications on Medicare payments and length of stay
(LOS). The Poisson regression model is applied to analyze the effects on the fre-
quency of claims. The logistic regression model is utilized to study the effects on
mortality. RESULTS: Results demonstrate that several two-way interactions such
as heart disease and eye disease, heart disease and hypertension are significant to
costs and LOS. The effects between kidney disease and cardiovascular disease are
significant in the Poisson regression model. The interaction effect between renal
disease and cardiovascular disease is significant tomortality.CONCLUSIONS:After
the study, we can conclude that for inpatients with other diabetes complications,
there are differences in health costs and health outcomes between the inpatients
who have cardiovascular disease and those who do not have. There also exist big
differences in outcomes between the patients who have renal disease and those
who do not have.
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A CLAIMS-BASED EMPIRIC APPROACH TO ASSESSING MEDICATION
POSSESSION FOR PATIENTS INITIATING THERAPY WITH INSULINS
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OBJECTIVES: An important challenge addressing researchers studying adherence
among insulin-requiring patients with diabetes is the discrepancy between the
point-of-sale (POS) entered days supply and the actual time of medication posses-
sion. Significant deviation between these two can result in misleading medication
passion ratio (MPR) estimates, especially in cases where the quantity dispensed is
known to differ significantly, as is the casewith insulin detemir delivered in a 15mL
FlexPen® (IDetFP) pack versus NPH insulin delivered in a 10mL vial. This research
expands upon an approach used by Klienman et al., and suggests an alternative
measure of medication possession for insulins. METHODS: Data were gathered
from a large US national payer retrospective claims database, and included only
patients 18 years of age with type 2 diabetes that had 2 retail pharmacy fills of
IDetFP or NPH vial in a 12-month observation period. Patients with claims for any
other insulin, other than the index insulin during the 12-month observation period,
were excluded. Median empirically-derived days supply (EDDS) estimates, based
on median time-to-next-refill intervals, and POS entered days supplies were com-
pared within and between cohorts. RESULTS: Median POS days supply estimates
were identical for both the IDetFP and NPH cohorts, 30.00 days for both; however,
median EDDS were significantly different between IDet and NPH cohorts, 45.00 vs.
36.00, respectively (p0.001). In addition, within-group comparisons of POS days
supply and EDDS in both cohorts revealed significant differences (p0.001 for both
tests). CONCLUSIONS: Drawing meaningful conclusions about adherence with in-
sulins using pharmacy claims remains a significant challenge. Our analysis dem-
onstrates that POS days supply entries, commonly used for adherence analysis,
may deviate substantially and significantly from EDDS estimates. This study ex-
plores a novel, alternative, and empirically-based approach to determining medi-
cation possession. Research to further refine this and suggest other alternative
methods should be encouraged.
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BETA-VERIFICATION OF A DIABETES MODELING FRAMEWORK AGAINST
PUBLISHED COHORT TRIALS
Furiak N, Bansal M, Gahn JC, Smolen H
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OBJECTIVES: To perform a beta-verification of a novel diabetesmodeling and anal-
ysis framework (DMAF) designed to accommodate growing demand for analysis on
ever-shifting special subpopulations, new interventions, and updated care algo-
rithms. A Monte Carlo microsimulation model assuming standard oral and subse-
quent insulin therapy generated mean outcomes as defined by recently published
trials: 1) ACCORD-BPLI; 2) ACCORD-GLI; 3) ASPEN; and 4) ADVANCE. METHODS:
Diabetes is increasing in prevalence, and its 20-year history of diabetes care has
witnessed a shift from treating complications to prevention based on evidence
from: The United Kingdom Prospective Diabetes Study, Diabetes Control and Com-
plications Trials, and the Wisconsin Epidemiological Study of Diabetic Retinopa-
thy. All have confirmed that tight control of hemoglobin A1c reduced the incidence
of complications. Recent trials of diabetics have evaluated targeted interventions
for clinical factors and impact on complication rates. Evidence from these trials
suggests that aggressive A1c targets may not be suitable for all patients. The evo-
lution of decision models for diabetes has paralleled that of care. Increased prev-
alence has placed pressure on health care costs and expectations that new inter-
ventions impart significant benefits. New evidence has in turn motivated
development of decisionmodels that evaluate new interventions, treatments, and
care algorithms. RESULTS: The DMAFwas reasonably consistent withwell-defined
composite endpoints for ASPEN (15.0% vs. 17.1%); ADVANCE: Secondary (10.5% vs.
9.6%), fatal MI (5.7% vs. 5.5%), all coronary events (11.9% vs. 10.3%); and ACCORD-
BPLI non-fatal MI (1.4% vs. 1.3%). DMAF showed results within orders ofmagnitude
for endpoints such as ASPEN angina (2.6% vs. 3.1%); ACCORD-BPLI: heart failure
(0.5% vs. 0.8%), major coronary event (3.1% vs. 2.4%), primary outcome (3.6% vs.
2.1%); ACC ORD-GLI non-fatal MI (6.5% vs. 4.6%). CONCLUSIONS: Trial outcomes
defined as “new or worsening” were not well-matched by DMAF due possibly to
uncertainty in definitions and suitability for modeling.
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